Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
  • C07C309/01—Sulfonic acids
  • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
  • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
  • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
  • C07C55/02—Dicarboxylic acids
  • C07C55/06—Oxalic acid
  • C07C55/07—Salts thereof
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
  • C07C55/02—Dicarboxylic acids
  • C07C55/10—Succinic acid
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
  • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
  • C07C57/13—Dicarboxylic acids
  • C07C57/15—Fumaric acid
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
  • C07C59/235—Saturated compounds containing more than one carboxyl group
  • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
  • C07C59/235—Saturated compounds containing more than one carboxyl group
  • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
  • C07C59/255—Tartaric acid
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
  • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
  • C07C69/84—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
  • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
  • C07B2200/13—Crystalline forms, e.g. polymorphs

Definitions

• Plasma kallikrein is a serine protease zymogen in blood that is converted to its catalytically active form by coagulation factor XIIa, and contributes to the innate inflammatory response and intrinsic cascade of blood coagulation.
• the mechanisms that lead to the activation of this pathway in vivo include interactions with polyphosphates released from activated platelets and deficiency of C1 inhibitor (C1-INH), the primary physiological inhibitor of pKal.
• BK bradykinin 2 receptor
• B1 and B2 receptors are expressed by vascular, glial, and neuronal cell types, with the highest levels of retinal expression detected in the ganglion cell layer and inner and outer nuclear layers. Activation of B1 and B2 receptors causes vasodilation and increases vascular permeability.
• HAE hereditary angioedema
• pKal is also associated with a number of disorders, such as hereditary angioedema (HAE), an autosomal dominant disease characterized by painful, unpredictable, recurrent attacks of inflammation affecting the hands, feet, face, abdomen, urogenital tract, and the larynx.
• HAE hereditary angioedema
• Prevalence for HAE is uncertain but is estimated to be approximately 1 case per 50,000 persons without known differences among ethnic groups.
• HAE is caused by deficient (Type I) or dysfunctional (Type II) levels of C1-INH, which inhibits pKal, bradykinin, and other serine proteases in the blood.
• HAE hereditary angioedema
• Chemical compounds can form one or more different pharmaceutically acceptable salts and/or solid forms, including amorphous and polymorphic crystal forms. Individual salts and solid forms of bioactive chemical compounds can have different properties.
• Figure 2 provides TGA/DSC curves for Compound 1 Form 1 (free base).
• Figure 3 provides X-ray powder diffraction (XRPD) pattern of Compound 1 Form 2 (free base).
• Figure 4 provides TGA/DSC curves for Compound 1 Form 2 (free base).
• Figure 5 provides X-ray powder diffraction (XRPD) pattern of Compound 1 Form 3 (free base).
• Figure 6 provides TGA/DSC curves for Compound 1 Form 3 (free base).
• Figure 7 provides X-ray powder diffraction (XRPD) pattern of Compound 3 Pattern 1 (L-malate).
• Figure 8 provides TGA/DSC curves for Compound 3 Pattern 1 (L-malate).
• Figure 9 provides X-ray powder diffraction (XRPD) pattern of Compound 4 Pattern 1 (succinate).
• Figure 10 provides TGA/DSC curves for Compound 4 Pattern 1 (succinate).
• Figure 11 provides X-ray powder diffraction (XRPD) pattern of Compound 5 Pattern 1 (phosphate).
• Figure 12 provides TGA/DSC curves for Compound 5 Pattern 1 (phosphate).
• Figure 13 provides X-ray powder diffraction (XRPD) pattern of Compound 6 Pattern 1 (oxalate).
• Figure 14 provides TGA/DSC curves for Compound 6 Pattern 1 (oxalate).
• Figure 15 provides X-ray powder diffraction (XRPD) pattern of Compound 6 Pattern 4 (oxalate).
• Figure 16 provides TGA/DSC curves for Compound 6 Pattern 4 (oxalate).
• Figure 17 provides overlay of Compound 1 Form 1 (free base) and Compound 7 Pattern 1 (L-tartrate).
• Figure 18 provides TGA/DSC curves for Compound 7 Pattern 1 (L-tartrate).
• Figure 19 provides X-ray powder diffraction (XRPD) pattern of Compound 9 Pattern 1 (fumarate).
• Figure 20 provides TGA/DSC curves for Compound 9 Pattern 1 (fumarate).
• Figure 21 provides thermodynamic stability diagram of different forms of Compound 1 (free base).
• Figure 22 provides the overlay of XRPD patterns of Compound 1 obtained from the synthetic procedure described in Example 1 (Compound 1 as synthesized), Compound 1 Form 1 (free base), and Compound 1 Form 2 (free base).
• DETAILED DESCRIPTION OF THE INVENTION General Description of Certain Aspects of the Invention: [0028] PCT patent application publication number WO2019/178129, filed March 12, 2019 and published September 19, 2019 (“the ‘129 publication”), the entirety of which is hereby incorporated herein by reference, describes certain plasma kallikerin (pKal) inhibitor compounds.
• Such compounds include N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)- 1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide: [0029]
• Compound 1 which is a free base, is one of many compounds identified as a small molecule inhibitor of pKal in the ‘129 publication. In the ‘129 publication, Compound 1 is identified as compound I-148 and its synthesis is described in detail at Example 148, which is reproduced herein for ease of reference.
• Compound 1 has shown potency against plasma kallikrein in an in vitro assay (See, e.g., Table 1 of the ‘129 publication). For example, the ‘129 publication reports that Compound 1 has an EC50 ⁇ 1 nM as measured in an in vitro kallikrein kinase assay. Accordingly, Compound 1 is useful for treating one or more disorders associated with activity of pKal.
• the present disclosure provides various free base solid forms of Compound 1, salt forms of Compound 1 and solid forms thereof, pharmaceutical compositions thereof, and methods of preparing solid forms of Compound 1 and salts and solid forms thereof.
• Salt forms and solid forms impart or may impart characteristics such as improved aqueous solubility, stability, absorption, bioavailability, and ease of formulation.
• the term “salt” refers to a salt or co-crystal of two or more (e.g., two) component molecules (e.g., Compound 1 and a co-former).
• a ⁇ pKa (pKa(base)- pKa- (acid)) ⁇ 1 generally will permit the formation of a salt compound where the two compounds are ionized.
• a provided solid form is a salt.
• a provided solid form is a co-crystal.
• Free base Forms of Compound 1 1.
• Compound 1 can exist in a variety of physical forms. For example, Compound 1 can be in solution, suspension, or in solid form. In certain embodiments, Compound 1 is in solid form. When Compound 1 is in solid form, said compound may be amorphous, crystalline, or a mixture thereof. Exemplary solid forms are described in more detail below.
• the present invention provides a form of Compound 1 substantially free of impurities.
• the term “substantially free of impurities” means that the compound contains no significant amount of extraneous matter. Such extraneous matter may include different forms of Compound 1, residual solvents, or any other impurities that may result from the preparation of, and/or isolation of, Compound 1.
• at least about 95% by weight of a form of Compound 1 is present.
• at least about 99% by weight of a form of Compound 1 is present.
• a form of Compound 1 is present in an amount of at least about 97.0, 97.5, 98.0, 98.5, 99.0, 99.5, or 99.8 weight percent where the percentages are based on the total weight of the composition.
• a form of compound 1 contains no more than about 3.0 area percent HPLC of total organic impurities and, in certain embodiments, no more than about 1.5 area percent HPLC total organic impurities relative to the total area of the HPLC chromatogram.
• a form of Compound 1 contains no more than about 1.0 area percent HPLC of any single impurity; no more than about 0.6 area percent HPLC of any single impurity, and, in certain embodiments, no more than about 0.5 area percent HPLC of any single impurity, relative to the total area of the HPLC chromatogram.
• the structure depicted for a form of Compound 1 is also meant to include all tautomeric forms of Compound 1. Additionally, structures depicted here are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms.
• Compound 1 can exist in a variety of solid forms. Exemplary such forms include polymorphs such as those described herein.
• Compound 1 is amorphous. In some embodiments, Compound 1 is amorphous, and is substantially free of crystalline compound 1.
• polymorph refers to the different crystal structures into which a compound, or a salt or co-crystal or solvate thereof, can crystallize.
• Compound 1 is a crystalline solid. In some embodiments, Compound 1 is a crystalline solid substantially free of amorphous Compound 1. As used herein, the term “substantially free of amorphous Compound 1” means that the compound contains no significant amount of amorphous Compound 1. In certain embodiments, at least about 95% by weight of crystalline Compound 1 is present. In still other embodiments of the invention, at least about 99% by weight of crystalline Compound 1 is present. [0040] It has been found that Compound 1 can exist in at least three distinct polymorphic forms. In certain embodiments, the present invention provides a polymorphic form of Compound 1 referred to herein as Form 1.
• the present invention provides a polymorphic form of Compound 1 referred to herein as Form 2. In certain embodiments, the present invention provides a polymorphic form of Compound 1 referred to herein as Form 3. [0041] In some embodiments, Compound 1 is in a polymorphic form substantially free of other polymorphic forms. In some embodiments, Compound 1 is in Form 1, substantially free from other free base forms of Compound 1. In some embodiments, Compound 1 is in Form 2, substantially free from other free base forms of Compound 1. In some embodiments, Compound 1 is in Form 3, substantially free from other free base forms of Compound 1. [0042] In some embodiments, Compound 1 is an anhydrate. In other embodiments, Compound 1 is a hydrate.
• Compound 1 Form 1 has at least 1, 2, 3, 4 or 5 X-ray Powder Diffraction (XRPD) peaks selected from the angles (2 theta ⁇ 0.2) listed in Table 1 below. Table 1. XRPD Peak Positions for Compound 1 Form 1 [0044] In some embodiments, Compound 1 Form 1 is characterized by an X-ray powder diffraction (XRPD) pattern having diffractions at angles (2 theta ⁇ 0.2) and corresponding d- spacing (angstroms ⁇ 0.2) of: Table 2.
• XRPD X-ray Powder Diffraction
• Compound 1 Form 1 is characterized in that it has one or more peaks in its X-ray powder diffraction pattern selected from those at about 11.8, 15.0, 17.0, 18.0, 19.4, and 23.5. In some embodiments, Compound 1 Form 1 is characterized in that it has two or more peaks in its X-ray powder diffraction pattern selected from those at about 11.8, 15.0, 17.0, 18.0, 19.4, and 23.5. In some embodiments, Compound 1 Form 1 is characterized in that it has three or more peaks in its X-ray powder diffraction pattern selected from those at about 11.8, 15.0, 17.0, 18.0, 19.4, and 23.5.
• Compound 1 Form 1 is characterized in that it has four or more peaks in its X-ray powder diffraction pattern selected from those at about 11.8, 15.0, 17.0, 18.0, 19.4, and 23.5. In some embodiments, Compound 1 Form 1 is characterized in that it has five or more peaks in its X-ray powder diffraction pattern selected from those at about 11.8, 15.0, 17.0, 18.0, 19.4, and 23.5. In some embodiments, Compound 1 Form 1 is characterized in that it has all six peaks in its X-ray powder diffraction pattern selected from those at about 11.8, 15.0, 17.0, 18.0, 19.4, and 23.5.
• Compound 1 Form 1 is characterized in that it has all six peaks in its X-ray powder diffraction pattern selected from those at about 11.8, 15.0, 17.0, 18.0, 19.4, and 23.5, corresponding to d-spacing (angstroms ⁇ 0.2) of 7.52, 5.92, 5.20, 4.93, 4.58, and 3.79 (respectively).
• d-spacing angstroms ⁇ 0.2
• the term “about”, when used in reference to a degree 2-theta value refers to the stated value ⁇ 0.2 degree 2-theta.
• the X-ray powder diffraction pattern of Compound 1 Form 1 is substantially similar to the XRPD provided in Figure 1.
• Compound 1 Form 2 has at least 1, 2, 3, 4 or 5 X-ray Powder Diffraction (XRPD) peaks selected from the angles (2 theta ⁇ 0.2) listed in Table 3 below. Table 3. XRPD Peak Positions for Compound 1 Form 2 [0049] In some embodiments, Compound 1 Form 2 is characterized by an X-ray powder diffraction (XRPD) pattern having diffractions at angles (2 theta ⁇ 0.2) and corresponding d- spacing (angstroms ⁇ 0.2) of: Table 4.
• XRPD X-ray Powder Diffraction
• Compound 1 Form 2 is characterized in that it has one or more peaks in its X-ray powder diffraction pattern selected from those at about 6.1, 8.0, 13.0, 17.0, 17.8, and 25.6. In some embodiments, Compound 1 Form 2 is characterized in that it has two or more peaks in its X-ray powder diffraction pattern selected from those at about 6.1, 8.0, 13.0, 17.0, 17.8, and 25.6.
• Compound 1 Form 2 is characterized in that it has three or more peaks in its X-ray powder diffraction pattern selected from those at about 6.1, 8.0, 13.0, 17.0, 17.8, and 25.6. In some embodiments, Compound 1 Form 2 is characterized in that it has four or more peaks in its X-ray powder diffraction pattern selected from those at about 6.1, 8.0, 13.0, 17.0, 17.8, and 25.6. In some embodiments, Compound 1 Form 2 is characterized in that it has five or more peaks in its X-ray powder diffraction pattern selected from those at about 6.1, 8.0, 13.0, 17.0, 17.8, and 25.6.
• Compound 1 Form 2 is characterized in that it has all six peaks in its X-ray powder diffraction pattern selected from those at about 6.1, 8.0, 13.0, 17.0, 17.8, and 25.6. In some embodiments, Compound 1 Form 2 is characterized in that it has all six peaks in its X-ray powder diffraction pattern selected from those at about 6.1, 8.0, 13.0, 17.0, 17.8, and 25.6, corresponding to d-spacing (angstroms ⁇ 0.2) of 14.52, 11.04, 6.81, 5.20, 4.98, and 3.48 (respectively).
• the X-ray powder diffraction pattern of Compound 1 Form 2 is substantially similar to the XRPD provided in Figure 3. [0052] Methods for preparing Compound 1 Form 2 are described infra. Compound 1 Form 3 [0053] In some embodiments, Compound 1 Form 3 has at least 1, 2, 3, 4 or 5 X-ray Powder Diffraction (XRPD) peaks selected from the angles (2 theta ⁇ 0.2) listed in Table 5 below. Table 5.
• XRPD X-ray Powder Diffraction
• Compound 1 Form 3 is characterized by an X-ray powder diffraction (XRPD) pattern having diffractions at angles (2 theta ⁇ 0.2) and corresponding d- spacing (angstroms ⁇ 0.2) of: Table 6.
• XRPD Peak Positions and d-Spacing for Compound 1 Form 3 [0055]
• the X-ray powder diffraction pattern of Compound 1 Form 3 is substantially similar to the XRPD provided in Figure 5.
• Methods for preparing Compound 1 Form 3 are described infra. II.
• Compound 1 and a co-former are combined to provide a species where Compound 1 and the co-former are, e.g., ionically bonded or are hydrogen bonded to form one of Compounds 2 through 11, described below.
• Compounds 2 through 11 can exist in a variety of physical forms.
• Compounds 2 through 11 can be in solution, suspension, or in solid form.
• Compounds 2 through 11 are in solid form. When Compounds 2 through 11 are in solid form, said compounds may be amorphous, crystalline, or a mixture thereof.
• the present invention provides a chemical species Compound 2 comprising Compound 1 and hydrochloric acid:
• the solid form of Compound 2 has a stoichiometry of (Compound 1):(hydrochloric acid) that is about 1:1.
• the solid form of Compound 2 has a stoichiometry of (Compound 1):(hydrochloric acid) that is about 1:2.
• the present invention provides a polymorphic form of Compound 2 referred to herein as Pattern 1. In certain embodiments, the present invention provides a polymorphic form of Compound 2 referred to herein as Pattern 2. In certain embodiments, the present invention provides a polymorphic form of Compound 2 referred to herein as Pattern 3. In certain embodiments, the present invention provides a polymorphic form of Compound 2 referred to herein as Pattern 4. In certain embodiments, the present invention provides a polymorphic form of Compound 2 referred to herein as Pattern 5. In certain embodiments, the present invention provides a polymorphic form of Compound 2 referred to herein as Pattern 6. In certain embodiments, the present invention provides a polymorphic form of Compound 2 referred to herein as Pattern 7.
• the present invention provides a polymorphic form of Compound 2 referred to herein as Pattern 8. In certain embodiments, the present invention provides a polymorphic form of Compound 2 referred to herein as Pattern 9. In certain embodiments, the present invention provides a polymorphic form of Compound 2 referred to herein as Pattern 10. In certain embodiments, the present invention provides a polymorphic form of Compound 2 referred to herein as Pattern 11. In certain embodiments, the present invention provides a polymorphic form of Compound 2 referred to herein as Pattern 12. In certain embodiments, the present invention provides a polymorphic form of Compound 2 referred to herein as Pattern 13.
• the present invention provides a chemical species Compound 3 comprising Compound 1 and L-malic acid: [0061] It is contemplated that Compound 3 can exist in a variety of physical forms. For example, Compound 3 can be in solution, suspension, or in solid form. In certain embodiments, Compound 3 is in solid form. When Compound 3 is in solid form, said compound may be amorphous, crystalline, or a mixture thereof.
• the solid form of Compound 3 has a stoichiometry of (Compound 1):(L-malic acid) that is about 1:1.
• the present invention provides Compound 3 substantially free of impurities.
• the term “substantially free of impurities” means that the compound contains no significant amount of extraneous matter. Such extraneous matter may include excess L-malic acid, excess Compound 1, residual solvents, or any other impurities that may result from the preparation of, and/or isolation of, Compound 3. In certain embodiments, at least about 95% by weight of Compound 3 is present.
• Compound 3 is present in an amount of at least about 97.0, 97.5, 98.0, 98.5, 99.0, 99.5, or 99.8 weight percent where the percentages are based on the total weight of the composition.
• Compound 3 contains no more than about 3.0 area percent HPLC of total organic impurities and, in certain embodiments, no more than about 1.5 area percent HPLC total organic impurities relative to the total area of the HPLC chromatogram.
• Compound 3 contains no more than about 1.0 area percent HPLC of any single impurity; no more than about 0.6 area percent HPLC of any single impurity, and, in certain embodiments, no more than about 0.5 area percent HPLC of any single impurity, relative to the total area of the HPLC chromatogram.
• the structure depicted for Compound 3 is also meant to include all tautomeric forms of Compound 3. Additionally, structures depicted here are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, compounds having the present structure except for the replacement of hydrogen by deuterium or tritium, or the replacement of a carbon by a 13 C- or 14 C-enriched carbon are within the scope of this invention.
• Compound 3 can exist in a variety of solid forms. Exemplary such forms include polymorphs such as those described herein. [0067] In some embodiments, Compound 3 is amorphous. In some embodiments, Compound 3 is amorphous, and is substantially free of crystalline Compound 3. [0068] In certain embodiments, Compound 3 is a crystalline solid. In other embodiments, Compound 3 is a crystalline solid substantially free of amorphous Compound 3. As used herein, the term “substantially free of amorphous Compound 3” means that the compound contains no significant amount of amorphous Compound 3. In certain embodiments, at least about 95% by weight of crystalline Compound 3 is present.
• Compound 3 can exist in at least one polymorphic form.
• the present invention provides a polymorphic form of Compound 3 referred to herein as Pattern 1.
• Compound 3 Pattern 1 [0070]
• Compound 3 Pattern 1 has at least 1, 2, 3, 4 or 5 X-ray Powder Diffraction (XRPD) peaks selected from the angles (2 theta ⁇ 0.2) listed in Table 7 below. Table 7.
• Compound 3 Pattern 1 is characterized by an X-ray powder diffraction (XRPD) pattern having diffractions at angles (2 theta ⁇ 0.2) and corresponding d-spacing (angstroms ⁇ 0.2) of: Table 8. XRPD Peak Positions and d-Spacing for Compound 3 Pattern 1 [0072] In some embodiments, Compound 3 Pattern 1 is characterized in that it has one or more peaks in its X-ray powder diffraction pattern selected from those at about 6.2, 12.7, 17.3, 20.4, 25.3, and 26.4.
• Compound 3 Pattern 1 is characterized in that it has two or more peaks in its X-ray powder diffraction pattern selected from those at about 6.2, 12.7, 17.3, 20.4, 25.3, and 26.4. In some embodiments, Compound 3 Pattern 1 is characterized in that it has three or more peaks in its X-ray powder diffraction pattern selected from those at about 6.2, 12.7, 17.3, 20.4, 25.3, and 26.4. In some embodiments, Compound 3 Pattern 1 is characterized in that it has four or more peaks in its X-ray powder diffraction pattern selected from those at about 6.2, 12.7, 17.3, 20.4, 25.3, and 26.4.
• Compound 3 Pattern 1 is characterized in that it has five or more peaks in its X-ray powder diffraction pattern selected from those at about 6.2, 12.7, 17.3, 20.4, 25.3, and 26.4. In some embodiments, Compound 3 Pattern 1 is characterized in that it has all six peaks in its X-ray powder diffraction pattern selected from those at about 6.2, 12.7, 17.3, 20.4, 25.3, and 26.4.
• Compound 3 Pattern 1 is characterized in that it has all six peaks in its X-ray powder diffraction pattern selected from those at about 6.2, 12.7, 17.3, 20.4, 25.3, and 26.4, corresponding to d- spacing (angstroms ⁇ 0.2) of 14.32, 6.97, 5.13, 4.34, 3.52, and 3.37 (respectively).
• the X-ray powder diffraction pattern of Compound 3 Pattern 1 is substantially similar to the XRPD provided in Figure 7.
• Methods for preparing Compound 3 Pattern 1 are described infra. 4.
• the present invention provides a chemical species Compound 4 comprising Compound 1 and succinic acid: Compound 4 [0076]
• the solid form of Compound 4 has a stoichiometry of (Compound 1):(succinic acid) that is about 1:1.
• the term “about”, when used in reference to a stoichiometric ratio refers to 1:(1 ⁇ 0.2) ratio of (Compound 1):(co-former, e.g., an acid), e.g., a 1:(1 ⁇ 0.2) ratio, a 1:(1 ⁇ 0.1) ratio, or a 1:(1 ⁇ 0.05) ratio.
• the present invention provides Compound 4 substantially free of impurities.
• the term “substantially free of impurities” means that the compound contains no significant amount of extraneous matter. Such extraneous matter may include excess succinic acid, excess Compound 1, residual solvents, or any other impurities that may result from the preparation of, and/or isolation of, Compound 4.
• at least about 95% by weight of Compound 4 is present.
• at least about 99% by weight of Compound 4 is present.
• Compound 4 is present in an amount of at least about 97.0, 97.5, 98.0, 98.5, 99.0, 99.5, or 99.8 weight percent where the percentages are based on the total weight of the composition.
• Compound 4 contains no more than about 3.0 area percent HPLC of total organic impurities and, in certain embodiments, no more than about 1.5 area percent HPLC total organic impurities relative to the total area of the HPLC chromatogram.
• Compound 4 contains no more than about 1.0 area percent HPLC of any single impurity; no more than about 0.6 area percent HPLC of any single impurity, and, in certain embodiments, no more than about 0.5 area percent HPLC of any single impurity, relative to the total area of the HPLC chromatogram.
• the structure depicted for Compound 4 is also meant to include all tautomeric forms of Compound 4. Additionally, structures depicted here are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, compounds having the present structure except for the replacement of hydrogen by deuterium or tritium, or the replacement of a carbon by a 13 C- or 14 C-enriched carbon are within the scope of this invention.
• Compound 4 can exist in a variety of solid forms. Exemplary such forms include polymorphs such as those described herein. [0081] In some embodiments, Compound 4 is amorphous. In some embodiments, Compound 4 is amorphous, and is substantially free of crystalline Compound 4. [0082] In certain embodiments, Compound 4 is a crystalline solid. In other embodiments, Compound 4 is a crystalline solid substantially free of amorphous Compound 4. As used herein, the term “substantially free of amorphous Compound 4” means that the compound contains no significant amount of amorphous Compound 4. In certain embodiments, at least about 95% by weight of crystalline Compound 4 is present.
• Compound 4 can exist in at least one polymorphic form.
• the present invention provides a polymorphic form of Compound 4 referred to herein as Pattern 1.
• Compound 4 Pattern 1 has at least 1, 2, 3, 4 or 5 X-ray Powder Diffraction (XRPD) peaks selected from the angles (2 theta ⁇ 0.2) listed in Table 9 below. Table 9.
• Compound 4 Pattern 1 is characterized by an X-ray powder diffraction (XRPD) pattern having diffractions at angles (2 theta ⁇ 0.2) and corresponding d-spacing (angstroms ⁇ 0.2) of: Table 10. XRPD Peak Positions and d-Spacing for Compound 4 Pattern 1
• Compound 4 Pattern 1 is characterized in that it has one or more peaks in its X-ray powder diffraction pattern selected from those at about 6.2, 10.2, 12.7, 17.3, 20.4, and 23.8. In some embodiments, Compound 4 Pattern 1 is characterized in that it has two or more peaks in its X-ray powder diffraction pattern selected from those at about 6.2, 10.2, 12.7, 17.3, 20.4, and 23.8. In some embodiments, Compound 4 Pattern 1 is characterized in that it has three or more peaks in its X-ray powder diffraction pattern selected from those at about 6.2, 10.2, 12.7, 17.3, 20.4, and 23.8.
• Compound 4 Pattern 1 is characterized in that it has four or more peaks in its X-ray powder diffraction pattern selected from those at about 6.2, 10.2, 12.7, 17.3, 20.4, and 23.8. In some embodiments, Compound 4 Pattern 1 is characterized in that it has five or more peaks in its X-ray powder diffraction pattern selected from those at about 6.2, 10.2, 12.7, 17.3, 20.4, and 23.8. In some embodiments, Compound 4 Pattern 1 is characterized in that it has all six peaks in its X-ray powder diffraction pattern selected from those at about 6.2, 10.2, 12.7, 17.3, 20.4, and 23.8.
• Compound 4 Pattern 1 is characterized in that it has all six peaks in its X-ray powder diffraction pattern selected from those at about 6.2, 10.2, 12.7, 17.3, 20.4, and 23.8, corresponding to d- spacing (angstroms ⁇ 0.2) of 14.26, 8.64, 6.95, 5.12, 4.35, and 3.73 (respectively).
• the X-ray powder diffraction pattern of Compound 4 Pattern is substantially similar to the XRPD provided in Figure 9.
• Methods for preparing Compound 4 Pattern 1 are described infra. 5.
• the present invention provides a chemical species Compound 5 comprising Compound 1 and phosphoric acid: Compound 5 [0090]
• the solid form of Compound 5 has a stoichiometry of (Compound 1):(phosphoric acid) that is about 1:1.
• the present invention provides Compound 5 substantially free of impurities.
• the term “substantially free of impurities” means that the compound contains no significant amount of extraneous matter. Such extraneous matter may include excess L-malic acid, excess Compound 1, residual solvents, or any other impurities that may result from the preparation of, and/or isolation of, Compound 5.
• Compound 5 is present in an amount of at least about 97.0, 97.5, 98.0, 98.5, 99.0, 99.5, or 99.8 weight percent where the percentages are based on the total weight of the composition.
• Compound 5 contains no more than about 3.0 area percent HPLC of total organic impurities and, in certain embodiments, no more than about 1.5 area percent HPLC total organic impurities relative to the total area of the HPLC chromatogram.
• Compound 5 contains no more than about 1.0% area percent HPLC of any single impurity; no more than about 0.6 area percent HPLC of any single impurity, and, in certain embodiments, no more than about 0.5 area percent HPLC of any single impurity, relative to the total area of the HPLC chromatogram.
• the structure depicted for Compound 5 is also meant to include all tautomeric forms of Compound 5. Additionally, structures depicted here are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, compounds having the present structure except for the replacement of hydrogen by deuterium or tritium, or the replacement of a carbon by a 13 C- or 14 C-enriched carbon are within the scope of this invention.
• Compound 5 can exist in a variety of solid forms. Exemplary such forms include polymorphs such as those described herein. [0095] In some embodiments, Compound 5 is amorphous. In some embodiments, Compound 5 is amorphous, and is substantially free of crystalline Compound 5. [0096] In certain embodiments, Compound 5 is a crystalline solid. In other embodiments, Compound 5 is a crystalline solid substantially free of amorphous Compound 5. As used herein, the term “substantially free of amorphous Compound 5” means that the compound contains no significant amount of amorphous Compound 5. In certain embodiments, at least about 95% by weight of crystalline Compound 5 is present.
• Compound 5 can exist in at least one polymorphic form.
• the present invention provides a polymorphic form of Compound 5 referred to herein as Pattern 1.
• Compound 5 Pattern 1 [0098]
• Compound 5 Pattern 1 has at least 1, 2, 3, 4 or 5 X-ray Powder Diffraction (XRPD) peaks selected from the angles (2 theta ⁇ 0.2) listed in Table 11 below. Table 11.
• Compound 5 Pattern 1 is characterized by an X-ray powder diffraction (XRPD) pattern having diffractions at angles (2 theta ⁇ 0.2) and corresponding d-spacing (angstroms ⁇ 0.2) of: Table 12. XRPD Peak Positions and d-Spacing for Compound 5 Pattern 1 [0100] In some embodiments, Compound 5 Pattern 1 is characterized in that it has one or more peaks in its X-ray powder diffraction pattern selected from those at about 4.7, 6.1, 17.0, 17.4, 18.1, and 24.6.
• Compound 5 Pattern 1 is characterized in that it has two or more peaks in its X-ray powder diffraction pattern selected from those at about 4.7, 6.1, 17.0, 17.4, 18.1, and 24.6. In some embodiments, Compound 5 Pattern 1 is characterized in that it has three or more peaks in its X-ray powder diffraction pattern selected from those at about 4.7, 6.1, 17.0, 17.4, 18.1, and 24.6. In some embodiments, Compound 5 Pattern 1 is characterized in that it has four or more peaks in its X-ray powder diffraction pattern selected from those at about 4.7, 6.1, 17.0, 17.4, 18.1, and 24.6.
• Compound 5 Pattern 1 is characterized in that it has five or more peaks in its X-ray powder diffraction pattern selected from those at about 4.7, 6.1, 17.0, 17.4, 18.1, and 24.6. In some embodiments, Compound 5 Pattern 1 is characterized in that it has all six peaks in its X-ray powder diffraction pattern selected from those at about 4.7, 6.1, 17.0, 17.4, 18.1, and 24.6.
• Compound 5 Pattern 1 is characterized in that it has all six peaks in its X-ray powder diffraction pattern selected from those at about 4.7, 6.1, 17.0, 17.4, 18.1, and 24.6, corresponding to d- spacing (angstroms ⁇ 0.2) of 18.68, 14.45, 5.20, 5.10, 4.91, and 3.62 (respectively). .
• the X-ray powder diffraction pattern of Compound 5 Pattern 1 is substantially similar to the XRPD provided in Figure 11. [0102] Methods for preparing Compound 5 Pattern 1 are described infra. 6.
• the present invention provides a chemical species Compound 6 comprising Compound 1 and oxalic acid: Compound 6 [0104]
• the solid form of Compound 6 has a stoichiometry of (Compound 1):(oxalic acid) that is about 1:1.
• the present invention provides Compound 6 substantially free of impurities.
• substantially free of impurities means that the compound contains no significant amount of extraneous matter.
• Such extraneous matter may include excess oxalic acid, excess Compound 1, residual solvents, or any other impurities that may result from the preparation of, and/or isolation of, Compound 6.
• at least about 95% by weight of Compound 6 is present.
• at least about 99% by weight of Compound 6 is present.
• Compound 6 is present in an amount of at least about 97.0, 97.5, 98.0, 98.5, 99.0, 99.5, or 99.8 weight percent where the percentages are based on the total weight of the composition.
• Compound 6 contains no more than about 3.0 area percent HPLC of total organic impurities and, in certain embodiments, no more than about 1.5 area percent HPLC total organic impurities relative to the total area of the HPLC chromatogram. In other embodiments, Compound 6 contains no more than about 1.0 area percent HPLC of any single impurity; no more than about 0.6 area percent HPLC of any single impurity, and, in certain embodiments, no more than about 0.5 area percent HPLC of any single impurity, relative to the total area of the HPLC chromatogram. [0107] The structure depicted for Compound 6 is also meant to include all tautomeric forms of Compound 6.
• structures depicted here are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms.
• compounds having the present structure except for the replacement of hydrogen by deuterium or tritium, or the replacement of a carbon by a 13 C- or 14 C-enriched carbon are within the scope of this invention.
• Compound 6 can exist in a variety of solid forms. Exemplary such forms include polymorphs such as those described herein.
• Compound 6 is amorphous.
• Compound 4 is amorphous, and is substantially free of crystalline Compound 6.
• Compound 6 is a crystalline solid.
• Compound 6 is a crystalline solid substantially free of amorphous Compound 6.
• substantially free of amorphous Compound 6 means that the compound contains no significant amount of amorphous Compound 6. In certain embodiments, at least about 95% by weight of crystalline Compound 6 is present. In still other embodiments of the invention, at least about 99% by weight of crystalline Compound 6 is present. [0111] It has been found that Compound 6 can exist in at least two polymorphic forms. In some embodiments, the present invention provides a polymorphic form of Compound 6 referred to herein as Pattern 1. In some embodiments, the present invention provides a polymorphic form of Compound 6 referred to herein as Pattern 4.
• Compound 6 Pattern 1 has at least 1, 2, 3, 4 or 5 X-ray Powder Diffraction (XRPD) peaks selected from the angles (2 theta ⁇ 0.2) listed in Table 13 below. Table 13. XRPD Peak Positions for Compound 6 Pattern 1
• Compound 6 Pattern 1 is characterized by an X-ray powder diffraction (XRPD) pattern having diffractions at angles (2 theta ⁇ 0.2) and corresponding d-spacing (angstroms ⁇ 0.2) of: Table 14. XRPD Peak Positions and d-Spacing for Compound 6 Pattern 1 [0114] In some embodiments, Compound 6 Pattern 1 is characterized in that it has one or more peaks in its X-ray powder diffraction pattern selected from those at about 4.7, 6.1, 18.7, 24.0, 24.2, and 24.6.
• Compound 6 Pattern 1 is characterized in that it has two or more peaks in its X-ray powder diffraction pattern selected from those at about 4.7, 6.1, 18.7, 24.0, 24.2, and 24.6. In some embodiments, Compound 6 Pattern 1 is characterized in that it has three or more peaks in its X-ray powder diffraction pattern selected from those at about 4.7, 6.1, 18.7, 24.0, 24.2, and 24.6. In some embodiments, Compound 6 Pattern 1 is characterized in that it has four or more peaks in its X-ray powder diffraction pattern selected from those at about 4.7, 6.1, 18.7, 24.0, 24.2, and 24.6.
• Compound 6 Pattern 1 is characterized in that it has five or more peaks in its X-ray powder diffraction pattern selected from those at about 4.7, 6.1, 18.7, 24.0, 24.2, and 24.6. In some embodiments, Compound 6 Pattern 1 is characterized in that it has all six peaks in its X-ray powder diffraction pattern selected from those at about 4.7, 6.1, 18.7, 24.0, 24.2, and 24.6.
• Compound 6 Pattern 1 is characterized in that it has all six peaks in its X-ray powder diffraction pattern selected from those at about 4.7, 6.1, 18.7, 24.0, 24.2, and 24.6, corresponding to d- spacing (angstroms ⁇ 0.2) of 18.88, 14.36, 4.73, 3.71, 3.67, and 3.62 (respectively).
• the X-ray powder diffraction pattern of Compound 6 Pattern 1 is substantially similar to the XRPD provided in Figure 13.
• Methods for preparing Compound 6 Pattern 1 are described infra.
• Compound 6 Pattern 4 has at least 1, 2, 3, 4 or 5 X-ray Powder Diffraction (XRPD) peaks selected from the angles (2 theta ⁇ 0.2) listed in Table 15 below. Table 15. XRPD Peak Positions for Compound 6 Pattern 4 [0118] In some embodiments, Compound 6 Pattern 4 is characterized by an X-ray powder diffraction (XRPD) pattern having diffractions at angles (2 theta ⁇ 0.2) and corresponding d-spacing (angstroms ⁇ 0.2) of: Table 16.
• XRPD X-ray Powder Diffraction
• Compound 6 Pattern 4 is characterized in that it has one or more peaks in its X-ray powder diffraction pattern selected from those at about 6.4, 11.9, 19.2, 26.1, 26.6, and 27.2. In some embodiments, Compound 6 Pattern 4 is characterized in that it has two or more peaks in its X-ray powder diffraction pattern selected from those at about 6.4, 11.9, 19.2, 26.1, 26.6, and 27.2.
• Compound 6 Pattern 4 is characterized in that it has three or more peaks in its X-ray powder diffraction pattern selected from those at about 6.4, 11.9, 19.2, 26.1, 26.6, and 27.2. In some embodiments, Compound 6 Pattern 4 is characterized in that it has four or more peaks in its X-ray powder diffraction pattern selected from those at about 6.4, 11.9, 19.2, 26.1, 26.6, and 27.2. In some embodiments, Compound 6 Pattern 4 is characterized in that it has five or more peaks in its X-ray powder diffraction pattern selected from those at about 6.4, 11.9, 19.2, 26.1, 26.6, and 27.2.
• Compound 6 Pattern 4 is characterized in that it has all six peaks in its X-ray powder diffraction pattern selected from those at about 6.4, 11.9, 19.2, 26.1, 26.6, and 27.2. In some embodiments, Compound 6 Pattern 4 is characterized in that it has all six peaks in its X-ray powder diffraction pattern selected from those at about 6.4, 11.9, 19.2, 26.1, 26.6, and 27.2, corresponding to d- spacing (angstroms ⁇ 0.2) of 13.89, 7.43, 4.63, 3.42, 3.35, and 3.27 (respectively). [0120] In certain embodiments, the X-ray powder diffraction pattern is substantially similar to the XRPD provided in Figure 15.
• the present invention provides a chemical species Compound 7 comprising Compound 1 and L-tartaric acid: [0123] In one embodiment, the solid form of Compound 7 has a stoichiometry of (Compound 1):(L-tartaric acid) that is about 1:1. [0124] In some embodiments, the present invention provides Compound 7 substantially free of impurities. As used herein, the term “substantially free of impurities” means that the compound contains no significant amount of extraneous matter.
• Such extraneous matter may include excess L-tartaric acid, excess Compound 1, residual solvents, or any other impurities that may result from the preparation of, and/or isolation of, Compound 7.
• at least about 95% by weight of Compound 7 is present.
• at least about 99% by weight of Compound 7 is present.
• Compound 7 is present in an amount of at least about 97.0, 97.5, 98.0, 98.5, 99.0, 99.5, or 99.8 weight percent where the percentages are based on the total weight of the composition.
• Compound 7 contains no more than about 3.0 area percent HPLC of total organic impurities and, in certain embodiments, no more than about 1.5 area percent HPLC total organic impurities relative to the total area of the HPLC chromatogram. In other embodiments, Compound 7 contains no more than about 1.0 area percent HPLC of any single impurity; no more than about 0.6 area percent HPLC of any single impurity, and, in certain embodiments, no more than about 0.5 area percent HPLC of any single impurity, relative to the total area of the HPLC chromatogram. [0126] The structure depicted for Compound 7 is also meant to include all tautomeric forms of Compound 7.
• structures depicted here are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms.
• compounds having the present structure except for the replacement of hydrogen by deuterium or tritium, or the replacement of a carbon by a 13 C- or 14 C-enriched carbon are within the scope of this invention.
• Compound 7 can exist in a variety of solid forms. Exemplary such forms include polymorphs such as those described herein.
• Compound 7 is amorphous.
• Compound 7 is amorphous, and is substantially free of crystalline Compound 7.
• Compound 7 is a crystalline solid.
• Compound 7 is a crystalline solid substantially free of amorphous Compound 7.
• substantially free of amorphous Compound 7 means that the compound contains no significant amount of amorphous Compound 7. In certain embodiments, at least about 95% by weight of crystalline Compound 7 is present. In still other embodiments of the invention, at least about 99% by weight of crystalline Compound 7 is present. [0130] It has been found that Compound 7 can exist in at least one polymorphic form. In some embodiments, the present invention provides a polymorphic form of Compound 7 referred to herein as Pattern 1. 8.
• the present invention provides a chemical species Compound 8 comprising Compound 1 and methanesulfonic acid: [0132] In one embodiment, the solid form of Compound 8 has a stoichiometry of (Compound 1):(methanesulfonic acid) that is about 1:1. [0133] In some embodiments, the present invention provides Compound 8 substantially free of impurities. As used herein, the term “substantially free of impurities” means that the compound contains no significant amount of extraneous matter.
• Such extraneous matter may include excess methanesulfonic acid, excess Compound 1, residual solvents, or any other impurities that may result from the preparation of, and/or isolation of, Compound 8.
• at least about 95% by weight of Compound 8 is present.
• at least about 99% by weight of Compound 8 is present.
• Compound 8 is present in an amount of at least about 97.0, 97.5, 98.0, 98.5, 99.0, 99.5, or 99.8 weight percent where the percentages are based on the total weight of the composition.
• Compound 8 contains no more than about 3.0 area percent HPLC of total organic impurities and, in certain embodiments, no more than about 1.5 area percent HPLC total organic impurities relative to the total area of the HPLC chromatogram. In other embodiments, Compound 8 contains no more than about 1.0 area percent HPLC of any single impurity; no more than about 0.6 area percent HPLC of any single impurity, and, in certain embodiments, no more than about 0.5 area percent HPLC of any single impurity, relative to the total area of the HPLC chromatogram. [0135] The structure depicted for Compound 8 is also meant to include all tautomeric forms of Compound 8.
• structures depicted here are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms.
• compounds having the present structure except for the replacement of hydrogen by deuterium or tritium, or the replacement of a carbon by a 13 C- or 14 C-enriched carbon are within the scope of this invention.
• Compound 8 can exist in a variety of solid forms. Exemplary such forms include polymorphs such as those described herein.
• Compound 8 is amorphous.
• Compound 8 is amorphous, and is substantially free of crystalline Compound 8.
• Compound 8 is a crystalline solid.
• Compound 8 is a crystalline solid substantially free of amorphous Compound 8.
• substantially free of amorphous Compound 8 means that the compound contains no significant amount of amorphous Compound 8. In certain embodiments, at least about 95% by weight of crystalline Compound 8 is present. In still other embodiments of the invention, at least about 99% by weight of crystalline Compound 8 is present. [0139] It has been found that Compound 8 can exist in at least one polymorphic form. In some embodiments, the present invention provides a polymorphic form of Compound 8 referred to herein as Pattern 1. In some embodiments, the present invention provides a polymorphic form of Compound 8 referred to herein as Pattern 2.
• the present invention provides a polymorphic form of Compound 8 referred to herein as Pattern 3. 9.
• Compound 9 (Fumaric acid ⁇ Compound 1)
• the present invention provides a chemical species Compound 9 comprising Compound 1 and fumaric acid: [0141]
• the solid form of Compound 9 has a stoichiometry of (Compound 1):(fumaric acid) that is about 1:1.
• the present invention provides Compound 9 substantially free of impurities.
• the term “substantially free of impurities” means that the compound contains no significant amount of extraneous matter.
• Such extraneous matter may include excess fumaric acid, excess Compound 1, residual solvents, or any other impurities that may result from the preparation of, and/or isolation of, Compound 9.
• at least about 95% by weight of Compound 9 is present.
• at least about 99% by weight of Compound 9 is present.
• Compound 9 is present in an amount of at least about 97.0, 97.5, 98.0, 98.5, 99.0, 99.5, or 99.8 weight percent where the percentages are based on the total weight of the composition.
• Compound 9 contains no more than about 3.0 area percent HPLC of total organic impurities and, in certain embodiments, no more than about 1.5 area percent HPLC total organic impurities relative to the total area of the HPLC chromatogram. In other embodiments, Compound 9 contains no more than about 1.0 area percent HPLC of any single impurity; no more than about 0.6 area percent HPLC of any single impurity, and, in certain embodiments, no more than about 0.5 area percent HPLC of any single impurity, relative to the total area of the HPLC chromatogram. [0144] The structure depicted for Compound 9 is also meant to include all tautomeric forms of Compound 9.
• structures depicted here are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms.
• compounds having the present structure except for the replacement of hydrogen by deuterium or tritium, or the replacement of a carbon by a 13 C- or 14 C-enriched carbon are within the scope of this invention.
• Compound 9 can exist in a variety of solid forms. Exemplary such forms include polymorphs such as those described herein.
• Compound 9 is amorphous.
• Compound 9 is amorphous, and is substantially free of crystalline Compound 9.
• Compound 9 is a crystalline solid.
• Compound 9 is a crystalline solid substantially free of amorphous Compound 9.
• substantially free of amorphous Compound 9 means that the compound contains no significant amount of amorphous Compound 9. In certain embodiments, at least about 95% by weight of crystalline Compound 9 is present. In still other embodiments of the invention, at least about 99% by weight of crystalline Compound 9 is present. [0148] It has been found that Compound 9 can exist in at least one polymorphic form. In some embodiments, the present invention provides a polymorphic form of Compound 9 referred to herein as Pattern 1.
• Compound 9 Pattern 1 has at least 1, 2, 3, 4 or 5 X-ray Powder Diffraction (XRPD) peaks selected from the angles (2 theta ⁇ 0.2) listed in Table 17 below. Table 17. XRPD Peak Positions for Compound 9 Pattern 1
• Compound 9 Pattern 1 is characterized by an X-ray powder diffraction (XRPD) pattern having diffractions at angles (2 theta ⁇ 0.2) and corresponding d-spacing (angstroms ⁇ 0.2) of: Table 18. XRPD Peak Positions and d-Spacing for Compound 9 Pattern 1 [0151] In some embodiments, Compound 9 Pattern 1 is characterized in that it has one or more peaks in its X-ray powder diffraction pattern selected from those at about 6.1, 10.8, 12.7, 20.4, 25.3, and 26.5.
• Compound 9 Pattern 1 is characterized in that it has two or more peaks in its X-ray powder diffraction pattern selected from those at about 6.1, 10.8, 12.7, 20.4, 25.3, and 26.5. In some embodiments, Compound 9 Pattern 1 is characterized in that it has three or more peaks in its X-ray powder diffraction pattern selected from those at about 6.1, 10.8, 12.7, 20.4, 25.3, and 26.5. In some embodiments, Compound 9 Pattern 1 is characterized in that it has four or more peaks in its X-ray powder diffraction pattern selected from those at about 6.1, 10.8, 12.7, 20.4, 25.3, and 26.5.
• Compound 9 Pattern 1 is characterized in that it has five or more peaks in its X-ray powder diffraction pattern selected from those at about 6.1, 10.8, 12.7, 20.4, 25.3, and 26.5. In some embodiments, Compound 9 Pattern 1 is characterized in that it has all six peaks in its X-ray powder diffraction pattern selected from those at about 6.1, 10.8, 12.7, 20.4, 25.3, and 26.5.
• Compound 6 Pattern 4 is characterized in that it has all six peaks in its X-ray powder diffraction pattern selected from those at about 6.1, 10.8, 12.7, 20.4, 25.3, and 26.5, corresponding to d- spacing (angstroms ⁇ 0.2) of 14.4, 8.19, 6.96, 4.34, 3.52, and 3.36 (respectively).
• the X-ray powder diffraction pattern of Compound 9 Pattern 1 is substantially similar to the XRPD provided in Figure 19.
• Methods for preparing Compound 9 Pattern 1 are described infra. III. Cocrystal forms 10.
• the present invention provides a chemical species Compound 10 comprising Compound 1 and methyl gallate: [0155] In one embodiment, the solid form of Compound 10 has a stoichiometry of (Compound 1):(methyl gallate) that is about 1:1. [0156] In some embodiments, the present invention provides Compound 10 substantially free of impurities. As used herein, the term “substantially free of impurities” means that the compound contains no significant amount of extraneous matter. Such extraneous matter may include excess methyl gallate, excess Compound 1, residual solvents, or any other impurities that may result from the preparation of, and/or isolation of, Compound 10.
• Compound 10 is present in an amount of at least about 97.0, 97.5, 98.0, 98.5, 99.0, 99.5, or 99.8 weight percent where the percentages are based on the total weight of the composition.
• Compound 10 contains no more than about 3.0 area percent HPLC of total organic impurities and, in certain embodiments, no more than about 1.5 area percent HPLC total organic impurities relative to the total area of the HPLC chromatogram.
• Compound 10 contains no more than about 1.0 area percent HPLC of any single impurity; no more than about 0.6 area percent HPLC of any single impurity, and, in certain embodiments, no more than about 0.5 area percent HPLC of any single impurity, relative to the total area of the HPLC chromatogram.
• the structure depicted for Compound 10 is also meant to include all tautomeric forms of Compound 10. Additionally, structures depicted here are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, compounds having the present structure except for the replacement of hydrogen by deuterium or tritium, or the replacement of a carbon by a 13 C- or 14 C-enriched carbon are within the scope of this invention.
• Compound 10 can exist in a variety of solid forms. Exemplary such forms include polymorphs such as those described herein. [0160] In some embodiments, Compound 10 is amorphous. In some embodiments, Compound 10 is amorphous, and is substantially free of crystalline Compound 10. [0161] In certain embodiments, Compound 10 is a crystalline solid. In other embodiments, Compound 10 is a crystalline solid substantially free of amorphous Compound 10. As used herein, the term “substantially free of amorphous Compound 10” means that the compound contains no significant amount of amorphous Compound 10. In certain embodiments, at least about 95% by weight of crystalline Compound 10 is present.
• At least about 99% by weight of crystalline Compound 10 is present.
• Compound 10 can exist in at least one polymorphic form.
• the present invention provides a polymorphic form of Compound 10 referred to herein as Pattern 1.
• Compound 11 Propyl gallate ⁇ Compound 1
• the present invention provides a chemical species Compound 11 comprising Compound 1 and propyl gallate:
• the solid form of Compound 11 has a stoichiometry of (Compound 1):(propyl gallate) that is about 1:1.
• the present invention provides Compound 11 substantially free of impurities.
• the term “substantially free of impurities” means that the compound contains no significant amount of extraneous matter. Such extraneous matter may include excess propyl gallate, excess Compound 1, residual solvents, or any other impurities that may result from the preparation of, and/or isolation of, Compound 11. In certain embodiments, at least about 95% by weight of Compound 11 is present. In still other embodiments of the invention, at least about 99% by weight of Compound 11 is present. [0166] According to one embodiment, Compound 11 is present in an amount of at least about 97, 97.5, 98.0, 98.5, 99, 99.5, 99.8 weight percent where the percentages are based on the total weight of the composition.
• Compound 11 contains no more than about 3.0 area percent HPLC of total organic impurities and, in certain embodiments, no more than about 1.5 area percent HPLC total organic impurities relative to the total area of the HPLC chromatogram. In other embodiments, Compound 11 contains no more than about 1.0 area percent HPLC of any single impurity; no more than about 0.6 area percent HPLC of any single impurity, and, in certain embodiments, no more than about 0.5 area percent HPLC of any single impurity, relative to the total area of the HPLC chromatogram. [0167] The structure depicted for Compound 11 is also meant to include all tautomeric forms of Compound 11.
• structures depicted here are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms.
• compounds having the present structure except for the replacement of hydrogen by deuterium or tritium, or the replacement of a carbon by a 13 C- or 14 C-enriched carbon are within the scope of this invention.
• Compound 11 can exist in a variety of solid forms. Exemplary such forms include polymorphs such as those described herein.
• Compound 11 is a crystalline solid. In other embodiments, Compound 11 is a crystalline solid substantially free of amorphous Compound 11.
• the term “substantially free of amorphous Compound 11” means that the compound contains no significant amount of amorphous Compound 11. In certain embodiments, at least about 95% by weight of crystalline Compound 11 is present. In still other embodiments of the invention, at least about 99% by weight of crystalline Compound 11 is present. [0170] It has been found that Compound 11 can exist in at least one polymorphic form. In some embodiments, the present invention provides a polymorphic form of Compound 11 referred to herein as Pattern 1. [0171] In some embodiments, Compound 11 is amorphous. In some embodiments, Compound 11 is amorphous, and is substantially free of crystalline Compound 11.
• “Acid” represents, e.g., any of the co-formers described herein.
• each of Compounds 2 through 9, and forms thereof are prepared from Compound 1 by combining Compound 1 with an appropriate acid to form the product Compound.
• another aspect of the present invention provides a method for preparing Compounds 2 through 9, and forms thereof, by combining Compound 1 with an appropriate acid to form the product Compound.
• the present invention provides a method for preparing Compound A: comprising steps of: combining Compound 1: with a suitable co-former (e.g., a suitable acid) and optionally a suitable solvent under conditions suitable for forming Compound A.
• a suitable co-former e.g., a suitable acid
• Compound 1 is treated with a co-former selected from: hydrochloric acid, sulfuric acid, p-toluenesulfonic acid, methanesulfonic acid, oxalic acid, L- malic acid, phosphoric acid, gentisic acid, salicylic acid, L-tartric acid, fumaric acid, citric acid, 4-amino salicylic acid, L-maleic acid, benzoic acid, succinic acid, nicotinic acid, sorbic acid, methyl gallate and propyl gallate.
• a suitable co-former is hydrochloric acid.
• a suitable co-former is sulfuric acid. [0179] In some embodiments, a suitable co-former is p-toluenesulfonic acid. [0180] In some embodiments, a suitable co-former is methanesulfonic acid. [0181] In some embodiments, a suitable co-former is oxalic acid. [0182] In some embodiments, a suitable co-former is L-malic acid. [0183] In some embodiments, a suitable co-former is phosphoric acid. [0184] In some embodiments, a suitable co-former is gentisic acid. [0185] In some embodiments, a suitable co-former is salicylic acid.
• a suitable co-former is L-tartaric acid.
• a suitable co-former is fumaric acid.
• a suitable co-former is citric acid.
• a suitable co-former is 4-amino salicylic acid.
• a suitable co-former is maleic acid.
• a suitable co-former is benzoic acid.
• a suitable co-former is succinic acid.
• a suitable co-former is nicotinic acid.
• a suitable co-former is sorbic acid.
• a suitable co-former is methyl gallate.
• a suitable co-former is propyl gallate.
• a suitable solvent may be any solvent system (e.g., one solvent or a mixture of solvents) in which Compound 1 and/or an acid are soluble, or are at least partially soluble.
• suitable solvents useful in the present invention include, but are not limited to protic solvents, aprotic solvents, polar aprotic solvent, or mixtures thereof.
• suitable solvents include an ether, an ester, an alcohol, a ketone, or a mixture thereof.
• a solvent is one or more organic alcohols.
• a solvent is chlorinated.
• a solvent is an aromatic solvent.
• a suitable solvent is methanol, ethanol, isopropanol, t- butanol, acetonitrile, tetrahydrofuran (THF), or acetone wherein said solvent is anhydrous or in combination with water or dichloromethane (DCM).
• suitable solvents include n-heptane, ethyl acetate, methyl ethyl ketone (MEK), tert-butyl methyl ether (TBME), isopropyl acetate (IPAC), methyl isobutyl ketone (MIBK), dimethylformamide (DMF), dimethylacetamide (DMAC), dimethylsulfoxide (DMSO), toluene, trifluorotoluene, anisole, chlorobenzene, cumene, or N-methylpyrrolidone (NMP).
• a suitable solvent is acetone.
• a suitable solvent is methanol.
• a suitable solvent is ethyl acetate. In some embodiments, a suitable solvent is a combination of said solvents. [0200] In some embodiments, the present invention provides a method for preparing a free base form of Compound 1 or Compound A, comprising one or more steps of removing a solvent and adding a solvent. In some embodiments, an added solvent is the same as the solvent removed. In some embodiments, an added solvent is different from a solvent removed. Means of solvent removal are known in the synthetic and chemical arts and include, but are not limited to, any of those described herein and in the Exemplification.
• a method for preparing a free base form of Compound 1 or Compound A comprises one or more steps of heating or cooling a preparation.
• a method for preparing a free base form of Compound 1 or Compound A comprises one or more steps of agitating or stirring a preparation.
• a method for preparing a free base form of Compound 1 or Compound A comprises a step of adding a suitable co-former to a solution or slurry of compound 1.
• a method for preparing a free base form of Compound 1 or Compound A comprises a step of adding a suitable acid to a solution or slurry of compound 1.
• a method for preparing a free base form of Compound 1 or Compound A comprises a step of heating.
• a free base form of Compound 1 or Compound A precipitates from the mixture.
• a free base form of Compound 1 or Compound A crystallizes from the mixture.
• a free base form of Compound 1 or Compound A crystallizes from solution following seeding of the solution (i.e., adding crystals of a free base form of Compound 1 or Compound A to the solution).
• a free base form of Compound 1 or Compound A can precipitate out of the reaction mixture, or be generated by removal of part or all of the solvent through methods such as evaporation, distillation, filtration (e.g., nanofiltration, ultrafiltration), reverse osmosis, absorption and reaction, by adding a suitable anti-solvent, for example but not limited to, heptane, cumene, toluene, and TBME, by cooling or by different combinations of these methods.
• a free base form of Compound 1 or Compound A is optionally isolated. It will be appreciated that a free base form of Compound 1 or Compound A may be isolated by any suitable physical means known to one of ordinary skill in the art.
• precipitated solid free base form of Compound 1 or Compound A is separated from the supernatant by filtration. In other embodiments, precipitated solid free base form of Compound 1 or Compound A is separated from the supernatant by decanting the supernatant. [0209] In certain embodiments, a free base form of Compound 1 or Compound A is separated from the supernatant by filtration. [0210] In certain embodiments, an isolated free base form of Compound 1 or Compound A is dried in air. In other embodiments isolated free base form of Compound 1 or Compound A is dried under reduced pressure, optionally at elevated temperature.
• compounds of the present invention are for use in medicine.
• compounds of the present invention are useful as serine protease zymogen inhibitor.
• compounds of the present invention are selective inhibitors of plasma kallikrein (pKal).
• the present invention provides methods of decreasing pKal activity. Such methods include contacting pKal with an effective amount of a provided compound. Therefore, the present invention further provides methods of inhibiting pKal activity by contacting pKal with a compound of the present invention.
• provided compounds are useful for the treatment of diseases and disorders that may be alleviated by inhibiting (i.e., decreasing) pKal activity.
• Diseases is meant diseases or disease symptoms.
• the present invention provides methods of treating pKal-mediated disorders in a subject in need thereof. Such methods include administering to the subject a therapeutically effective amount of a provided compound.
• Exemplary pKal-mediated disorders include edema, which refers to swelling in the whole body of a subject or a part thereof due to inflammation or injury when small blood vessels become leaky and releases fluid into nearby tissues.
• the edema is hereditary angioedema (HAE).
• the edema occurs in eyes, e.g., diabetic macular edema (DME).
• DME diabetic macular edema
• the present disclosure provides methods of inhibiting the activity of pKal.
• the application provides a method of inhibiting the activity of pKal in vitro via contacting any of the compounds described herein with pKal molecules in a sample, such as a biological sample.
• the application provides a method of inhibiting the activity of pKal in vivo via delivering an effective amount of any of the compounds described herein to a subject in need of the treatment through a suitable route.
• provided methods comprise administering to a subject in need thereof (e.g., a subject such as a human patient with edema) any of the compounds described herein.
• the methods comprise administering a compound of 1-11, or a pharmaceutically acceptable composition thereof, to a subject in need thereof.
• the method comprises administering a pharmaceutical composition comprising a compound of 1-11.
• the subject to be treated by any of the methods described herein is a human patient having, suspected of having, or at risk for edema, for example, HAE or DME.
• a subject having an edema can be identified by routine medical examination, e.g., laboratory tests.
• a subject suspected of having an edema might show one or more symptoms of the disease/disorder.
• a subject at risk for edema can be a subject having one or more of the risk factors associated with the disease, for example, deficiency in C1 inhibitor (C1-INH) as for HAE.
• C1-INH C1 inhibitor
• provided herein are methods of alleviating one or more symptoms of HAE in a human patient who is suffering from an HAE attack. Such a patient can be identified by routine medical procedures. An effective amount of one or more of the provided compounds can be given to the human patient via a suitable route, for example, those described herein.
• the compounds described herein may be used alone, or may be used in combination with other anti-HAE agents, for example but not limited to, a C1 esterase inhibitor (e.g., Cinryze ® or Berinert ® ), a pKal inhibitor (e.g., ecallantide or lanadelumab) or a bradykinin B2 receptor antagonist (e.g., Firazyr ® ).
• a C1 esterase inhibitor e.g., Cinryze ® or Berinert ®
• a pKal inhibitor e.g., ecallantide or lanadelumab
• a bradykinin B2 receptor antagonist e.g., Firazyr ®
• an effective amount of one or more of the compounds can be given to the human patient via a suitable route, for example, those described herein.
• the compounds described herein may be used alone, or may be used in combination with other anti-HAE agents, for example but not limited to, a C1 esterase inhibitor (e.g., Cinryze ® or Berinert ® ), a pKal inhibitor (e.g., ecallantide or lanadelumab) or a bradykinin B2 receptor antagonist (e.g., Firazyr ® ).
• a C1 esterase inhibitor e.g., Cinryze ® or Berinert ®
• a pKal inhibitor e.g., ecallantide or lanadelumab
• a bradykinin B2 receptor antagonist e.g., Firazyr ®
• Patients suitable for such prophylactic treatment may be human subjects having history of HAE attacks (e.g., human subjects experiencing more than 2 attacks per month).
• patients suitable for the prophylactic treatment may be human subjects having no HAE attack history but bearing one or more risk factors for HAE (e.g., family history, genetic defects in C1- INH gene, etc.)
• Such prophylactic treatment may involve the compounds described herein as the sole active agent, or involve additional anti-HAE agents, such as those described herein.
• provided herein are methods for preventing or reducing edema in an eye of a subject (e.g., a human patient).
• the human patient is a diabetic having, suspected of having, or at risk for diabetic macular edema (DME).
• DME is the proliferative form of diabetic retinopathy characterized by swelling of the retinal layers, neovascularization, vascular leak, and retinal thickening in diabetes mellitus due to leaking of fluid from blood vessels within the macula.
• an effective amount of one or more of the compounds described herein, or pharmaceutically acceptable salts thereof may be delivered into the eye of the subject where treatment is needed.
• the compound may be delivered by intraocular injection, or intravitreal injection.
• a subject may be treated with the compound as described herein, either as the sole active agent, or in combination with another treatment for DME.
• treatment for DME include laser photocoagulation, steroids, VEGF pathway targeting agents (e.g., Lucentis® (ranibizumab) or Eylea ® (aflibercept)), and/or anti-PDGF agents.
• the methods disclosed herein comprise administering to the subject an effective amount of a compound of 1-11.
• the effective amount is a therapeutically effective amount.
• the effective amount is a prophylactically effective amount.
• the subject being treated is an animal.
• the animal may be of either sex and may be at any stage of development.
• the subject is a mammal.
• the subject being treated is a human.
• the subject is a domesticated animal, such as a dog, cat, cow, pig, horse, sheep, or goat.
• the subject is a companion animal, such as a dog or cat.
• the subject is a livestock animal, such as a cow, pig, horse, sheep, or goat.
• the subject is a zoo animal.
• the subject is a research animal such as a rodent (e.g., mouse, rat), dog, pig, or non-human primate.
• the animal is a genetically engineered animal. In certain embodiments, the animal is a transgenic animal.
• Certain methods described herein may comprise administering one or more additional pharmaceutical agent(s) in combination with the compounds described herein.
• the additional pharmaceutical agent(s) may be administered at the same time as the compound of 1- 11, or at different times than the compound of 1-11.
• the compound of Formulae 1- 11 and any additional pharmaceutical agent(s) may be on the same dosing schedule or different dosing schedules. All or some doses of the compound of 1-11 may be administered before all or some doses of an additional pharmaceutical agent, after all or some does an additional pharmaceutical agent, within a dosing schedule of an additional pharmaceutical agent, or a combination thereof.
• the timing of administration of the compound of Formulae 1-11 and additional pharmaceutical agents may be different for different additional pharmaceutical agents.
• the additional pharmaceutical agent comprises an agent useful in the treatment of an edema, such as HAE or DME. Examples of such agents are provided herein.
• Assays [0224] To develop useful pKal inhibitors, candidate inhibitors capable of decreasing pKal activity may be identified in vitro. The activity of the inhibitor compounds can be assayed utilizing methods known in the art and/or those methods presented herein.
• compositions comprising any of the compounds described herein (e.g., any of Compounds 1-11) or any of the compounds described herein (e.g., any of Compounds 1-11) in combination with a pharmaceutically acceptable excipient (e.g., carrier).
• a pharmaceutically acceptable excipient e.g., carrier
• the pharmaceutical compositions include optical isomers, diastereomers, or pharmaceutically acceptable salts of the inhibitors disclosed herein.
• a “pharmaceutically acceptable carrier,” as used herein refers to pharmaceutical excipients, for example, pharmaceutically, physiologically, acceptable organic or inorganic carrier substances suitable for enteral or parenteral application that do not deleteriously react with the active agent.
• Suitable pharmaceutically acceptable carriers include water, salt solutions (such as Ringer's solution), alcohols, oils, lipids, gelatins, and carbohydrates such as lactose, amylose or starch, fatty acid esters, hydroxymethycellulose, and polyvinyl pyrrolidine.
• Such preparations can be sterilized and, if desired, mixed with auxiliary agents such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, coloring, and/or aromatic substances and the like that do not deleteriously react with the compounds of the invention.
• auxiliary agents such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, coloring, and/or aromatic substances and the like that do not deleteriously react with the compounds of the invention.
• the compounds of the invention can be administered alone or can be coadministered to the
• Coadministration is meant to include simultaneous or sequential administration of the compounds individually or in combination (more than one compound).
• the preparations can also be combined, when desired, with other active substances (e.g. to reduce metabolic degradation).
• Formulations [0229] Compounds of the present invention can be prepared and administered in a wide variety of oral, parenteral, and topical dosage forms.
• the compounds of the present invention can be administered by injection (e.g. intravenously, intramuscularly, intracutaneously, subcutaneously, intraduodenally, or intraperitoneally).
• the compounds described herein can be administered by inhalation, for example, intranasally.
• the compounds of the present invention can be administered transdermally.
• compositions comprising a pharmaceutically acceptable carrier or excipient and one or more compounds of the invention.
• pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules.
• a solid carrier can be one or more substance that may also act as diluents, flavoring agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material.
• the carrier is a finely divided solid in a mixture with the finely divided active component.
• the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.
• the powders and tablets preferably contain from 5% to 70% of the active compound.
• Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like.
• preparation is intended to include the formulation of the active compound with encapsulating material as a carrier providing a capsule in which the active component with or without other carriers, is surrounded by a carrier, which is thus in association with it.
• a carrier providing a capsule in which the active component with or without other carriers, is surrounded by a carrier, which is thus in association with it.
• cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid dosage forms suitable for oral administration.
• a low melting wax such as a mixture of fatty acid glycerides or cocoa butter
• Liquid form preparations include solutions, suspensions, and emulsions, for example, water or water/propylene glycol solutions.
• liquid preparations can be formulated in solution in aqueous polyethylene glycol solution.
• particularly suitable admixtures for the compounds of the invention are injectable, sterile solutions, preferably oily or aqueous solutions, as well as suspensions, emulsions, or implants, including suppositories.
• carriers for parenteral administration include aqueous solutions of dextrose, saline, pure water, ethanol, glycerol, propylene glycol, peanut oil, sesame oil, polyoxyethylene-block polymers, and the like. Ampoules are convenient unit dosages.
• the compounds of the invention can also be incorporated into liposomes or administered via transdermal pumps or patches.
• Pharmaceutical admixtures suitable for use in the present invention include those described, for example, in Pharmaceutical Sciences (17th Ed., Mack Pub. Co., Easton, PA) and WO 96/05309. [0236]
• Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavors, stabilizers, and thickening agents as desired.
• Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well-known suspending agents.
• viscous material such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well-known suspending agents.
• solid form preparations that are intended to be converted, shortly before use, to liquid form preparations for oral administration.
• Such liquid forms include solutions, suspensions, and emulsions.
• These preparations may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.
• the pharmaceutical preparation is preferably in unit dosage form.
• the preparation is subdivided into unit doses containing appropriate quantities of the active component.
• the unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules.
• the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.
• the quantity of active component in a unit dose preparation may be varied or adjusted according to the particular application and the potency of the active component.
• the composition can, if desired, also contain other compatible therapeutic agents. Examples [0240] The examples below are meant to illustrate certain embodiments of the invention, and not to limit the scope of the invention.
• XRPD X-ray powder diffraction
• Dissolution data were collected over 4 pH sectors (pH 2.0, 5.5, 6.5, and 7.4) for a total of 2 hours – 30 minutes per sector, with UV spectra collected every 30 seconds. A stir speed of 225 rpm was used with a 10 mm path length probe. The IDR was calculated based on the surface area of the 3/6/8 mm disc recess used (28.3 mm2 surface area). XRPD analysis was performed on all samples, both after compression of the material into the disc recess, and post dissolution analysis to observe any change in form. XRPD diffractograms were collected on the Bruker C2.
• Example 1 N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6- cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide (Compound 1) [0246] The synthesis of Compound 1 is described in detail at Example 148 of the ‘897 application, which is reproduced herein for ease of reference. Synthesis of 5-cyclopropylpyridin-2-amine.
• Example 2 Solid Forms of Compound 1 (Free base) [0253] Studies were undertaken to identify various new forms (e.g., solid forms) of Compound 1. Solubility Study [0254] Compound 1 obtained from the synthetic procedure described in Example 1 was found to show limited solubility in most of the organic solvents assessed (Table 22). In all solvents assessed, the material showed solubility of ⁇ 10 mg/mL at 25 °C. Solubility of >10 mg/mL was only observed in DMSO, NMP and MeOH:DCM 1:3 at 50 °C. Table 22. Solubility of Compound 1 in Various Solvents
• FIG. 1 provides an XRPD Compound 1 Form 1.
• Figure 2 provides TGA/DSC curves for Compound 1 Form 1.
• Compound 1 Form 2 can be prepared from amorphous form of Compound 1. 393 mg amorphous form of Compound 1 was charged to a 100 mL HEL polyblock vial.
• Compound 1 Form 3 can be prepared from amorphous form of Compound 1. 502 mg amorphous form of Compound 1 was charged to a 20 mL scintillation vial. To this, acetic acid (5 vol) was added and the sample heated to 50 °C on a Polar Bear with 500 rpm magnetic stirring to give a clear brown solution. This solution was cooled to 20 °C at 1 °C/min, whereupon acetonitrile (15 vol) was added dropwise to give a white precipitate. The sample was then stirred for a further 10 minutes prior to isolation by filtration.
• Amorphous form of Compound 1 was shown to convert to Form 1 upon heating to 150 °C, post GVS analysis and after storage at conditions of 40 °C/75%RH and 25 °C/97%RH for one week.
• Competitive slurries performed on a mixture of Form 1 and Form 2 showed that in the majority of experimental conditions investigated, Form 1 is the more thermodynamically stable polymorph.
• Competitive Slurry between Compound 1 Form 1 and Form 3 120 mg of both Compound 1 Form 3 and Compound 1 Form 1 were dispensed into a 20 mL vial. These were mixed, and then aliquots (20 mg) of this mixture were dispensed into HPLC vials and 90 vol (1.8 mL) selected solvents added.
• the isolated HCl Salt - Pattern 4 material was observed to change to HCl salt - Pattern 9.
• the HCl salts isolated in the preliminary salt formation experiments were deemed unsuitable for further investigation due to the extensive polymorphism exhibited by the HCl salts, and the complex thermal behaviour of all isolated HCl salts. Based on the salt formation results and the observations made on introduction of the counter-ion, acetone, methanol and ethyl acetate were selected as the solvents for further salt experiments. 2.
• these seven salt forms are identified from the experiment with L-malic acid, succinic acid, phosphoric acid, oxalic acid, L-tartaric acid, methanesulfonic acid, and fumaric acid.
• the rest of the salt forms e.g., sulfate salts, HCl salts, etc., exhibited complex thermal behavior typified by multiple endotherms at low temperature, or changed XRPD pattern after storage at conditions of 40 °C/75%RH for one week, and were deemed unsuitable for further scale-up and characterization.
• Example 4 Compound 3 (L-malate salt) Compound 3 Compound 3 Pattern 1
• Compound 3 Pattern 1 was isolated from the experiment performed using ethyl acetate as the solvent.
• Compound 3 Form 1 was shown to contain 0.7 molar equivalents of L-malic acid by 1 H-NMR spectroscopy. Slight changes were observed in the XRPD pattern of the material after storage at conditions of 40 °C/75%RH for one week.
• Scale-up Compound 1 obtained from the synthetic procedure described in Example 1 was charged to an HEL polyblock 100 mL vial.
• Figure 7 provides the XRPD pattern of the Compound 3 Pattern 1.
• Figure 8 provides the TGA/DSC curves of Compound 3 Pattern 1. The figure shows an endotherm (possibly melting/decomposition) at 187.2 oC (onset temperature) and a weight loss of 1.9% up to 150 oC.
• TGA analysis of Compound 3 Pattern 1 shows the start of thermal decomposition to occur at approximately 190 °C.
• the DSC trace of the scaled-up material contained a single endotherm with an onset at 187.2 °C (82.9 J/g).
• Compound 4 Pattern 1 was unchanged as evidenced by XRPD after storage for one week at 40 °C/75%RH.
• Scale-up Compound 1 obtained from the synthetic procedure described in Example 1 was charged to an HEL polyblock 100 mL vial. Acetone (100 vol, 50 mL) was subsequently charged to the vial and the resulting suspension was heated to 50 °C with 500 rpm suspended magnetic stirring. To this, one equivalent succinic acid (1 M in MeOH) was added to give a suspension. The suspension was held isothermally for 16 hours with stirring, and aliquots were removed and analyzed by XRPD. After 16 hours, conversion was observed to have occurred.
• the DSC trace of the scaled-up material contained a single endotherm with an onset at 223.4 °C (171 J/g), whereas the DSC trace of material obtained from the screening experiments showed two thermal events.
• GVS analysis of the material showed it to be non-hygroscopic with a 0.16 % mass increase observed between 0 and 90 %RH, and no observed change to the material was evidenced by XRPD post GVS analysis. The material was shown to be unchanged by XRPD after storage for one week at conditions of 40 °C/75%RH and 25 °C/97%RH.
• Example 6 Compound 5 (phosphate salt) Compound 5 Compound 5 Pattern 1 [0299] Compound 5 Pattern 1 was isolated from the screening experiment performed in acetone.
• Compound 6 Pattern 2 was then heated to 175 °C at a rate of 10 °C in a TGA pan, held isothermally for 5 minutes, then cooled to ambient temperature to obtain Compound 6 Pattern 4.
• the TGA thermogram of the material which showed no mass loss corresponding to desolvation demonstrated the material to be a solvent- free form.
• the TGA thermogram was seen to contain a mass loss between 200 and 260 °C corresponding to 0.84 molar equivalents of oxalic acid. The temperature of this mass loss coincides with an endotherm in the DSC trace of the material (onset 223.8 °C, 215 J/g).
• Compound 6 Pattern 4 can be prepared according to the following procedure: Compound 1 obtained from the synthetic procedure described in Example 1 (500 mg) was charged to a 100 mL round bottom flask. To this, 50 vol (25 mL) MeCN:H 2 O 1:1 was added and the suspension heated to 50 °C. To this, two equivalents of oxalic acid (1 M in THF) were added and clarification of the suspension was observed. The solution was stirred isothermally for 30 minutes, then cooled to 5 °C at 0.1 °C/min.
• Compound 7 Pattern 1 Compound 7 Form 1 was isolated from the experiments performed using acetone or ethyl acetate as solvent. The material was shown to contain 0.87 molar equivalents of L-tartaric acid by 1 H-NMR spectroscopy. The material was unchanged as evidenced by XRPD after storage for one week at 40 °C/75%RH. [0319] Scale-up: Compound 1 obtained from the synthetic procedure described in Example 1 was charged to an HEL polyblock 100 mL vessel. Acetone (100 vol, 50 mL) was charged to the vessel and the resulting suspension was heated to 50 °C with 500 rpm suspended magnetic stirring. One equivalent of L-tartaric acid (1 M in THF) was added to the suspension.
• Example 9 Compound 8 (mesylate salt) Compound 8 Pattern 1, 2, and 3 [0323] In total three mesylate salts were isolated from the experiments performed. Mesylate salt – Pattern 1 was isolated from the acetone experiment after addition of one equivalent of methanesulfonic acid. This material was shown to contain 0.93 molar equivalents of methanesulfonic acid and contained two broad endotherms in its DSC trace. Storage of the material for one week at conditions of 40 °C/75%RH resulted in changes to its XRPD pattern with peaks corresponding to Compound 1 Form 1 being present.
• the material isolated from the screening experiments was shown to contain 0.4 molar equivalents of fumaric acid by 1 H-NMR, and the sole endotherm in the DSC thermogram had a shoulder.
• the increase in fumaric acid equivalents as evidenced by 1 H-NMR, and the single peak in the DSC thermogram indicates the isolated material to be more phase pure than that obtained from screening.
• GVS analysis of the material showed it to be slightly hygroscopic with a 0.6 % mass increase observed between 0 and 90 %RH, and no observed change to the material was evidenced by XRPD post GVS analysis.
• the material was shown to be unchanged by XRPD after storage for one week at conditions of 40 °C/75%RH and 25 °C/97%RH.
• Example 11 Solid Form Solubility and Scalability [0331] Seven of the eight solid forms selected for scale-up were successfully isolated from the experiments performed, with only the mesylate – Pattern 3 not obtained at 500 mg scale. Of the seven solid forms successfully scaled-up, only the L-tartrate was shown to be poorly crystalline and hygroscopic. The remaining solid forms, L-malate, succinate, phosphate, oxalate, and fumarate, were observed to be stable under storage, had single endotherms in their respective DSC traces and exhibited reduced hygroscopicity in GVS analysis. The tabulated IDR sector 1 average values of the obtained solid forms and the stable free base Compound 1 Form 1 are shown in Table 47.
• Compound 6 Pattern 4 is more thermodynamically stable than Compound 6 Pattern 1 in competitive slurry experiments. A scalable solution-based and operationally simple crystallization procedure for the isolation of phase pure Compound 6 Pattern 4 in high yield, purity and low residual solvent content was identified.
• Example 12 Compound 10 (Methyl Gallate Cocrystal) Compound 10 Form 1 [0333] 50 mg Compound 1 was dispensed into a 2 mL stainless-steel milling jar containing one stainless steel milling ball, and to this 1 molar equivalent of methyl gallate was charged. THF (35 ⁇ L) was charged to the vial, and was milled on a Retsch mill for 30 minutes at 30 Hz. An aliquot was isolated and analyzed by XRPD.
• Example 13 Compound 11 (Propyl Gallate Cocrystal) Compound 11 Form 1 [0335] 50 mg Compound 1 was dispensed into a 2 mL stainless-steel milling jar containing one stainless steel milling ball, to this 1 molar equivalent of propyl gallate was charged. THF (35 ⁇ l) was charged to the vial, and this was milled on a Retsch mill for 30 minutes at 30 Hz. An aliquot was isolated and analyzed by XRPD.
• Embodiment 1 A solid form of Compound 2, comprising Compound 1 and hydrochloric acid: Embodiment 2. The solid form of embodiment 1, where the solid form is Compound 2 Pattern 2. Embodiment 3. The solid form of embodiment 1, where the solid form is Compound 2 Pattern 4. Embodiment 4. The solid form of embodiment 1, where the solid form is Compound 2 Pattern 9. Embodiment 5.
• Embodiment 6 The solid form of embodiment 5, where the solid form is Compound 7 Pattern 1 and is characterized by a differential scanning calorimetry (DSC) endotherm having a minima at about 199.0 °C.
• Embodiment 7. The solid form of any one of embodiments 5 and 6, characterized by an about 0.6% mass increase between 0 and 90%RH by gravimetric vapour sorption (GVS) analysis.
• Embodiment 8. A solid form of Compound 8, comprising Compound 1 and methanesulfonic acid: Embodiment 9.
• the solid form of embodiment 8, where the solid form is Compound 8 Pattern 1.
• Embodiment 10 The solid form of embodiment 8, where the solid form is Compound 8 Pattern 2.
• Embodiment 13 The solid form of embodiment 8, where the solid form is Compound 8 Pattern 3.
• Embodiment 12 A solid form of Compound 9, comprising Compound 1 and fumaric acid: Embodiment 13.
• XRPD X-ray powder diffraction
• Embodiment 15 The solid form of embodiment 12, where the solid form is Compound 9 Pattern 1 and is characterized by an X-ray powder diffraction (XRPD) pattern having five or more diffractions at angles (2 theta ⁇ 0.2) of 6.1, 10.8, 12.7, 20.4, 25.3, and 26.5.
• Embodiment 18 The solid form of embodiment 12, where the solid form is Compound 9 Pattern 1 and is characterized by an X-ray powder diffraction (XRPD) pattern having diffractions at angles (2 theta ⁇ 0.2) of: Embodiment 19.
• Embodiment 20 The solid form of any one of embodiments 12-19, characterized by a differential scanning calorimetry (DSC) endotherm having a minima at about 251.9 °C.
• Embodiment 21 The solid form of any one of embodiments 12-20, characterized by an about 0.6% mass increase between 0 and 90%RH by gravimetric vapour sorption (GVS) analysis.
• Embodiment 22 A solid form of Compound 10, comprising Compound 1 and methyl gallate:
• Embodiment 23 A solid form of Compound 11, comprising Compound 1 and propyl gallate:

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Cardiology (AREA)
• Heart & Thoracic Surgery (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Priority Applications (9)

Applications Claiming Priority (2)

Publications (2)

Family

ID=75870731

Family Applications (1)

Country Status (9)

Families Citing this family (1)

Citations (2)

Family Cites Families (4)

• 2021
  • 2021-04-16 EP EP25178752.9A patent/EP4623913A3/en active Pending
  • 2021-04-16 EP EP21724430.0A patent/EP4136091B1/en active Active
  • 2021-04-16 ES ES21724430T patent/ES3035604T3/es active Active
  • 2021-04-16 US US17/919,212 patent/US20230167132A1/en active Pending
  • 2021-04-16 DK DK21724430.0T patent/DK4136091T3/da active
  • 2021-04-16 WO PCT/US2021/027620 patent/WO2021211930A1/en not_active Ceased
  • 2021-04-16 PL PL21724430.0T patent/PL4136091T3/pl unknown
  • 2021-04-16 FI FIEP21724430.0T patent/FI4136091T3/fi active
  • 2021-04-16 PT PT217244300T patent/PT4136091T/pt unknown
  • 2021-04-16 JP JP2022562728A patent/JP2023522331A/ja active Pending
• 2025
  • 2025-07-22 JP JP2025122305A patent/JP2025142238A/ja active Pending

Patent Citations (2)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events